Epidiolex epidyolex?

What is Epidyolex (Epidiolex) and how does it compare to Epidyolex?

Epidyolex (Epidiolex) is a prescription medication approved by the US FDA in 2020 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome in patients two years of age or older.

Epidyolex Patent Information

According to DrugPatentWatch.com , the Epidyolex patent was issued on May 12, 2020, (US11744442B2) with a compound formula listed as Cannabidiol (C21H30O2) that has the potential to expire in 2035.

How does Epidiolex compare to Epidyolex?

Since 'Epidiolex' is also known for the brand name 'Epidyolex' this would mean both names are one and the same with the exception of their generic names. Epidyolex (Epidiolex) is manufactured by Greenwich Biosciences, Inc.

What is the main benefit of Epidyolex?

Epidyolex's primary mechanism is an anticonvulsant, reducing the frequency of seizures in LGS and Dravet syndrome.

Side Effects of Epidyolex

According to studies, common side effects include sleepiness, diarrhea, fatigue, vomiting, and fever [2].

Clinical Data for Epidyolex

Clinical trials have shown Epidyolex to be effective in reducing the frequency of seizures in patients with LGS [3].

Pricing Information

The cost for a month's supply of Epidyolex can range from $3,300 to $4,200.

Regulatory Status

The FDA has approved Epidyolex for use in the US for treatment of seizures in LGS and Dravet syndrome.

Sources:

[1] DrugPatentWatch.com. (2020). US11744442B2 Patent Information.
[2] Greenwich Biosciences, Inc. (2020). Epidyolex Prescribing Information.
[3] FDA. (2020). Epidyolex.